Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A‐I [Human]) to Enhance Cholesterol Efflux Capacity

CSL112 (apolipoprotein A‐I [human]) is a novel intravenous formulation of plasma‐derived apolipoprotein A‐I (apoA‐I) that enhances cholesterol efflux capacity. Renal impairment is a common comorbidity in acute myocardial infarction patients and is associated with impaired lipid metabolism. The aim o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Pharmacol
Autores principales: Gille, Andreas, Duffy, Danielle, Tortorici, Michael A., Wright, Samuel D., Deckelbaum, Lawrence I., D'Andrea, Denise M.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2018
Materias:
Special Populations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6587782/
https://ncbi.nlm.nih.gov/pubmed/30452776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1337
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares